Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.37 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17054986 | 0.94 | MAPT (0.55) | MAPTPOLBGAALMNACHRNB2 | |
| SCHEMBL12041915 | 0.90 | MAPT (0.44) | MAPTPOLBGAALMNACHRNB2 | |
| Hydrochloric Acid SCHEMBL382302 | 0.88 | MAPT (0.43) | MAPTPOLBGAALMNACHRNB2 | |
| SCHEMBL31247582 | 0.86 | POLB (0.44) | MAPTPOLBGAALMNACHRNB2 | |
| SCHEMBL31661424 | 0.82 | MAPT (0.43) | MAPTPOLBGAALMNACHRNB2 | |
| SCHEMBL30116099 | 0.82 | MAPT (0.43) | MAPTPOLBGAALMNACHRNB2 | |
| SCHEMBL31661421 | 0.79 | MAPT (0.36) | MAPTPOLBGAALMNACHRNB2 | |
| SCHEMBL381064 | 0.77 | ALDH1A1 (0.59) | MAPTLMNARAB9A | |
| SCHEMBL14919183 | 0.75 | MAPT (0.47) | MAPTPOLBCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL31580426 | 0.75 | ALDH1A1 (0.52) | MAPTPOLBGAACHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101072758-B | Quinazoline derivatives | ASTRAZENECA AB | 2013-07-31 | — | — | CN | disclosed |
| US-20120165351-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| US-8153643-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2012-04-10 | — | — | US | disclosed |
| EP-1802591-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-01-11 | — | — | EP | disclosed |
| US-20090233924-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | PLE PATRICK | 2009-02-05 | — | — | US | disclosed |
| CN-101072758-A | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2007-11-14 | — | — | CN | disclosed |
| EP-1802591-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| EP-1802608-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040520-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006040526-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | AQP3, AQP1, F12 | MAPT 3649/4885POLB 2260/4885GAA 3392/4885 |
| US-20090233924-A1 | Quinazoline derivatives | AQP1, PGF, F12 | MAPT 3010/4885POLB 1660/4885GAA 2241/4885 |
| US-20120165351-A1 | QUINAZOLINE DERIVATIVES | AQP1, F12, AQP3 | MAPT 2983/4885POLB 1971/4885GAA 2740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.